Compared with PD-1 monotherapy, combined immunotherapeutic targeting of CXCR2+ neutrophils (AZD5069, a CXCR2 inhibitor) and PD-1 in a MASH-HCC orthotopic mouse model resulted in increased survival [174]. This evidence concerns the gene CXCR2 and hepatocellular carcinoma.